Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
 ____________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934

March 26, 2009
Date of Report (Date of earliest event reported)
___________________________________________________________

ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
___________________________________________________________

    State of New York
1-10113
11-0853640
(State of Other Jurisdiction
(Commission File Number)
(I.R.S. Employer
of Incorporation)
  
Identification Number)

616 N. North Court, Suite 120
 Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)

(847) 705-7709
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
 
 
Item 8.01       Other Events.

On March 26, 2009 we issued a press release announcing that Garth Boehm, Ph.D. has been named Vice President, Modified Release Dosage Form Development and is expected to commence employment with us in May 2009.  A copy of the press release is furnished as Exhibit 99.1.

Item 9.01       Financial Statements and Exhibits.
 
Exhibit
Number
 Description
   
99.1
Press Release dated March 26, 2009 Announcing the Appointment of Dr. Garth Boehm as Vice President of Modified Release Dosage Form Development.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  ACURA PHARMACEUTICALS, INC.  
       
 
By:
/s/ Peter A. Clemens  
    Peter A. Clemens  
    Senior Vice President & Chief FinancialOfficer  
       
 
Date: March 26, 2009
 
 
Exhibit
Number
 Description
   
99.1
Press Release dated March 26, 2009 Announcing the Appointment of Dr. Garth Boehm as Vice President of Modified Release Dosage Form Development.